JOACOB J. LOKICH, M.D.; CHERYL MOORE, R.N.
The delivery of cancer chemotherapy by continuous infusion either for 5 days or for protracted durations has become common because of the substantial alleviation of toxicity, particularly acute gastrointestinal effects and cumulative drug effects (1). Short-term (120-hour or 5-day) infusions are commonly used for the delivery of fluorouracil (2), vinblastine (3), and doxorubicin (4). In a series of phase I and II trials of protracted infusion chemotherapy (5), we have seen an unusual dermatologic syndrome involving the palms and soles that limits the ability to continue treatment.
A prodrome of dysesthesias develops in the palms and soles that is initially
Learn more about subscription options.
Register Now for a free account.
LOKICH JJ, MOORE C. Chemotherapy-Associated Palmar-Plantar Erythrodysesthesia Syndrome. Ann Intern Med. 1984;101:798–800. doi: 10.7326/0003-4819-101-6-798
Download citation file:
Published: Ann Intern Med. 1984;101(6):798-800.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only